Clinical trials: Cutaneous Squamous Cell Carcinoma (CSCC)
Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers
In this clinical phase I, non-randomized, open-label, uncontrolled, interventional, multi-center trial, 20 adult subjects (≥ 18 years of age) with advanced non-melanoma skin cancers will receive a fixed dose of 0.1 mg of…
- Conditions
- Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Non-Melanoma Skin Cancers
- Trial name
- NCT04160065
- Testing
- IFx-Hu2.0
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- TuHURA Biosciences, Inc.
Cutaneous Squamous Cell Carcinoma (CSCC)
Pucotenlimab Combined With Becotatug Vedotin in Advanced Cutaneous Squamous Cell Carcinoma
Study Design The study plans to enroll 38 patients. A Simon's two-stage design is employed. Based on historical data, the objective response rate (ORR) for patients meeting the inclusion criteria and receiving PD-1 inhibitor…
- Trial name
- NCT07394244
- Testing
- Pucotenlimab, Becotatug Vedotin
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Fudan University
Cutaneous Squamous Cell Carcinoma, Skin Cancer
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
This is study is to evaluate the safety and efficacy of cosibelimab in special populations with advanced cutaneous squamous cell carcinoma (CSCC).
- Trial name
- NCT07426484
- Testing
- Cosibelimab, Prednisone, Sirolimus
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Dana-Farber Cancer Institute
Cutaneous Squamous Cell Carcinoma (CSCC)
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
This study will test a study drug called cemiplimab to see if it can help treat early-stage Cutaneous Squamous Cell Carcinoma (CSCC), a type of skin cancer. Cemiplimab works by helping the immune system to kill cancer cells.
- Trial name
- NCT06585410
- Testing
- Cemiplimab, Standard of care
- Where
- 53 sites in United States, Australia
- Volunteers
- 369 people
- Sponsor
- Regeneron Pharmaceuticals
Cutaneous Squamous Cell Carcinoma (CSCC)
Usefulness of Post-Operative Radiotherapy in High-grade Cutaneous Squamous Cell Carcinoma: an Observational Study
Post-operative radiotherapy (PORT) is currently considered as the second most important therapy to treat high-grade cutaneous squamous cell carcinoma.
- Trial name
- PORTSCC (NCT06879964)
- Where
- Italy
- Volunteers
- 120 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Melanoma (Skin), Squamous Cell Carcinoma of the Skin
Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC
This study evaluates intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma.
- Conditions
- Melanoma (Skin), Squamous Cell Carcinoma of the Skin, Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Adenoid Cystic
- Trial name
- NCT03291002
- Testing
- CV8102, CV8102 + anti-PD-1 therapy
- Where
- 22 sites in Austria, France and 3 more
- Volunteers
- 98 people
- Sponsor
- CureVac
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
CK-301 (cosibelimab) is a fully human monoclonal antibody of IgG1 subtype that directly binds to Programmed Death-Ligand 1 (PD-L1) and blocks its interactions with the Programmed Death-1 (PD-1) and B7.1 receptors.
- Conditions
- Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell, Malignant Mesothelioma, Advanced
- Trial name
- NCT03212404
- Testing
- CK-301 (cosibelimab)
- Where
- 48 sites in Australia, France and 7 more
- Volunteers
- 272 people
- Sponsor
- Checkpoint Therapeutics, Inc.
Cutaneous Squamous Cell Carcinoma in Situ (CSCCis)
Safety, Tolerability, and Efficacy Study of CLL442 in Patients With Cutaneous Squamous Cell Carcinoma in Situ (SCCis)
The purpose of this first in human and proof of concept study is to characterize the safety, tolerability and initial efficacy of CLL442 in patients with Squamous Cell Carcinoma in situ (SCCis) to enable further clinical…
- Trial name
- NCT03333694
- Testing
- Cutaneous Cream application
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Skin Cancer
Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin
The goal of this clinical research study is to learn if Tarceva ® (erlotinib) when taken before and after radiation and/or surgery can help to control aggressive cutaneous squamous cell carcinoma.
- Trial name
- NCT01059305
- Testing
- Erlotinib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
Cutaneous Melanoma, Mucosal Melanoma
A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors
The purpose of this trial is to find the maximum tolerated and recommended Phase 2 dose of KUP-101A and to evaluate its safety and tolerability.
- Conditions
- Cutaneous Melanoma, Mucosal Melanoma, Cutaneous Squamous Cell Carcinoma (CSCC), Merkel Cell Carcinoma of Skin
- Trial name
- NCT07600476
- Testing
- KUP-101A
- Where
- 3 sites in Germany
- Volunteers
- 21 people
- Sponsor
- Kupando GmbH
Skin Cancer, Cutaneous Squamous Cell Carcinoma (CSCC)
A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision
This study is investigating the effects on immune cells of injecting the influenza vaccine (also known as "flu shot") into cutaneous squamous cell carcinoma (CSCC) tumors prior to having standard-of-care Mohs excision surgery.
- Conditions
- Skin Cancer, Cutaneous Squamous Cell Carcinoma (CSCC), Cutaneous Squamous Cell Cancer
- Trial name
- NCT06664151
- Testing
- Fluzone Trivalent
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Dana-Farber Cancer Institute
Advanced Cutaneous Squamous Cell Carcinoma
Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma
The goals of this study are to evaluate the clinical benefit and safety of cemiplimab in participants with metastatic (nodal or distant) Cutaneous Squamous Cell Carcinoma (CSCC), or unresectable locally advanced CSCC.
- Trial name
- NCT02760498
- Testing
- cemiplimab
- Where
- 78 sites in United States, Australia and 6 more
- Volunteers
- 432 people
- Sponsor
- Regeneron Pharmaceuticals
Cutaneous Squamous Cell Carcinoma
Real World Study on the Use of Cemiplimab in Adult Patients in UK
The primary objective is to describe the real-world clinical effectiveness of cemiplimab in patients with locally advanced cutaneous squamous cell carcinoma (laCSCC) or metastatic cutaneous squamous cell carcinoma (mCSCC) treated…
- Trial name
- REACT-CEMI (NCT05493826)
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 110 people
- Sponsor
- Sanofi
Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer
A Study of VET3-TGI in Patients With Solid Tumors
VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by…
- Conditions
- Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer
- Trial name
- STEALTH-001 (NCT06444815)
- Testing
- VET3-TGI, Atezolizumab
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- KaliVir Immunotherapeutics
Basal Cell Carcinoma of Skin, Cutaneous Squamous Cell Carcinoma (CSCC)
Impact of Preoperative High-Frequency Ultrasound Cutaneous Lesion Extent Assessment on Excision Margin Positivity in Head and Neck Skin Cancer, and the Relationship Between Preoperative Assessment Methods, Inadequate Excision Margins, and Tumor Recurrence
Non-melanoma skin cancers (NMSC), particularly basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC), are the most common malignancies in Caucasians, with the majority of tumors located in the head and neck due…
- Conditions
- Basal Cell Carcinoma of Skin, Cutaneous Squamous Cell Carcinoma (CSCC), Cutaneous Squamous Cell Carcinoma in Situ (CSCCis), Cutaneous Squamous Cell Carcinoma of the Head and Neck
- Trial name
- HFUS-CLEAR (NCT07361666)
- Testing
- High-Frequency Ultrasound, Dermoscopy
- Where
- Poland
- Volunteers
- 400 people
- Sponsor
- Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych i Administracji
Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck
Pembrolizumab for the Treatment of Locally Advanced and/or Recurrent Orbital or Periocular Cutaneous Squamous Cell Carcinoma
This phase II trial studies how well pembrolizumab works in treating patients with orbital (eye socket) and/or periorbital (surrounding the eye socket) cutaneous squamous cell cancer (cSCC) that has spread to nearby tissue or…
- Conditions
- Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
- Trial name
- NCT06580054
- Testing
- Computed Tomography, Digital Photography, Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Michigan Rogel Cancer Center
Carcinoma, Squamous Cell, Skin Neoplasms
A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)
This is a two-part (Phase 2/Phase 3) study of intismeran autogene, an individualized neoantigen therapy (INT), plus pembrolizumab in participants with locally resectable advanced cutaneous squamous cell carcinoma (LA cSCC).
- Trial name
- INTerpath-007 (NCT06295809)
- Testing
- Pembrolizumab, Intismeran autogene, Surgery
- Where
- 106 sites in United States, Argentina and 18 more
- Volunteers
- 46 people
- Sponsor
- Merck Sharp & Dohme LLC
Skin Cancer, Cutaneous Squamous Cell Carcinoma (CSCC)
A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Transplant Recipients
A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Organ Transplant Recipients This study is designed to evaluate whether a topical 5% niacinamide cream can help prevent skin cancer in organ…
- Conditions
- Skin Cancer, Cutaneous Squamous Cell Carcinoma (CSCC), Actinic Keratosis (AK), Organ Transplant Recipient
- Trial name
- NCT07286318
- Testing
- Topical niacinamide 5% cream, Sunscreen
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Marissa Lobl
Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma
TIL Therapy in cSCC and MCC
The purpose of this research study is to test the safety and effectiveness of a tumor-infiltrating lymphocyte (TIL) cellular therapy, also called LN-145 or lifileucel, and chemotherapy in combination with Interleukin-2 (IL-2) to…
- Conditions
- Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma, Skin Cancer
- Trial name
- NCT07288073
- Testing
- LN-145, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Karam Khaddour, MD, MS
Cutaneous Squamous Cell Carcinoma, Skin Cancers - Squamous Cell Carcinoma
Microneedle Array Plus Doxorubicin in Cutaneous Squamous Cell Cancer (cSCC)
The purpose of this study is to test a new method of experimental treatment for cutaneous squamous cell skin cancer, using small adhesive-like patches (a micro-needle applicator or MNA for short), which have dozens of very small…
- Trial name
- cSCC (NCT05377905)
- Testing
- Microneedle Array Doxorubicin (MNA-D)
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Falo, Louis, MD